ArticleFrontiers in immunology2026
Network meta-analysis of first-line R-CHOP-based regimens in MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Double-expressor lymphoma (DEL), characterized by concurrent overexpression of MYC and BCL2 without gene rearrangements, represents 20%-30% of DLBCL and confers inferior outcomes with standard R-CHOP. However, no head-to-head trials comparing novel R-CHOP-based regimens specifically in DEL exist. We conducted a frequentist network meta-analysis to compare four modified R-CHOP regimens in treatment-naïve DEL patients. PubMed, EMBASE, Cochrane Library, and Web of Science were searched through December 2025. The efficacy analysis included four studies (CAVALLI, DEB, POLARIX, Randomised Evaluation of Molecular guided therapy for Diffuse Large B-cell lymphoma with Bortezomib (REMoDL-B); 1,016 DEL patients) evaluating Pola-R-CHP, Ven-R-CHOP, VR-CHOP, and CR-CHOP versus R-CHOP in a star-shaped network in which all interexperimental comparisons are purely indirect through the common R-CHOP comparator. For progression-free survival (PFS), Pola-R-CHP was the only regimen achieving statistical significance (HR = 0.65, 95% CI = 0.45-0.94; SUCRA = 76.1%), reducing progression risk by 35%. A supplementary Bayesian analysis confirmed this finding (posterior probability of HR < 1: 90.2%). No regimen significantly improved overall survival (OS). CR-CHOP showed the most favorable OS trend (HR = 0.77, 95% CI = 0.53-1.13; SUCRA = 69.8%). Safety analysis from intention-to-treat populations revealed that Ven-R-CHOP significantly increased grade 3-4 thrombocytopenia (OR = 17.24), neutropenia (OR = 3.42), and anemia (OR = 3.29), whereas Pola-R-CHP demonstrated a safety profile comparable to R-CHOP (any grade 3-4 AE: OR = 1.04). Sensitivity analyses excluding CAVALLI (historical control design), using alternative DEL definitions for REMoDL-B, and excluding REMoDL-B confirmed robustness. Pola-R-CHP may offer a favorable benefit-risk profile in DEL; however, this is based on indirect, subgroup-level evidence of moderate-to-low certainty, and prospective DEL-specific trials are needed for confirmation. The study protocol was registered on INPLASY (registration number: INPLASY202630036; DOI: 10.37766/inplasy2026.3.0036).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.